Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of the Efficacy and Safety of Iruplinalkib(WX-0593) in ALK-positive Advanced Lung Adenocarcinoma Following Lorlatinib Treatment

NCT07374614 is registered in ClinicalTrials.gov with Peking University Shenzhen Hospital as lead sponsor.

NCT NCT07374614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07374614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of the Efficacy and Safety of Iruplinalkib(WX-0593) in ALK-positive Advanced Lung Adenocarcinoma Following Lorlatinib Treatment
Lead sponsor
Peking University Shenzhen Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 31, 2026
Completion date
December 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk, iruplinalkib, lorlatinib, non-small cell lung cancer, observational study, real-world study